AI Screening System For Blindness Associated With Diabetes Gets FDA Nod

The US FDA has cleared an AI-based diagnostic from Israeli firm AEYE Health that screens for diabetic retinopathy, a leading cause of blindness.

Diabetic Eye
• Source: Shutterstock

AEYE Health has developed an automated diagnostic tool that could prevent millions of diabetics from losing their sight.

The Tel Aviv based digital health company recently announced it received 510(k) clearance from the US Food and Drug Administration for its screening system to detect retina damage in patients...

More from Regulation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.